Oncology Biomarker Discovery
Various Cancers
Research/DiscoveryActive
Key Facts
About Seer Inc
Seer is a commercial-stage proteomics company focused on making the proteome—the entire set of proteins in a biological system—broadly accessible to researchers and clinicians. Its core technology, the Proteograph Product Suite, utilizes engineered nanoparticles and liquid chromatography-mass spectrometry (LC-MS) to perform deep, unbiased, and rapid proteomic analysis from minimal sample volumes. The company aims to transform the understanding of biology and disease by providing scalable tools that overcome the historical limitations of proteomics, positioning itself at the forefront of the next generation of life science research and diagnostics.
View full company profileOther Various Cancers Drugs
| Drug | Company | Phase |
|---|---|---|
| Retifanlimab | Eli Lilly | Phase 2/3 |
| Imfinzi (durvalumab) | AstraZeneca | Approved |
| Lynparza (olaparib) | Merck | Commercial |
| Oncology Portfolio | Pfizer | Phase 1-3 |
| PD-1 Inhibitor | Akeso | Phase 2/3 |
| Mitoxantrone Liposome | CSPC Pharmaceutical Group Limited | Phase 3 |
| Biosimilar Bevacizumab | Cipla | Commercial |
| Tazverik (tazemetostat) | Eisai | Commercial |
| Oncology Generics | Aurobindo Pharma | Commercial |
| Opdivo (nivolumab) | Ono Pharmaceutical | Approved |
| Oncology APIs (e.g., Sorafenib, Lenalidomide) | Laurus Labs | Commercial/Filed |
| Tumor Marker Portfolio (PSA, CA125, etc.) | H.U. Group Holdings | Commercial |